Non-Annexin A7 messenger RNAs with partial complementarity

Non-Annexin A7 (ANXA7) messenger RNAs with partial complementarity refers to a diverse set of mRNA transcripts that are not the intended therapeutic target but share sequence similarity with the ANXA7 gene [1][4]. This concept is critical in the development of RNA-targeted therapies, such as antisense oligonucleotides (ASOs) and small interfering RNAs (siRNAs), which rely on Watson-Crick base pairing for specificity [2]. If a therapeutic agent designed to silence ANXA7 binds to these non-target mRNAs, it can lead to unintended gene knockdown, a phenomenon known as an off-target effect [2]. Such interactions can cause cellular toxicity or alter biological pathways unrelated to the intended treatment, posing a significant safety risk [2][4]. Consequently, rigorous bioinformatic screening and experimental validation are required to ensure that ANXA7-targeting drugs do not cross-react with these partially complementary sequences [4]. The specific identity of these non-target mRNAs depends entirely on the unique sequence of the drug candidate being evaluated [2].

Other names

Off-target transcriptsPartially complementary mRNAsNon-target mRNA sequencesNon-ANXA7 mRNAs

Unintended sequence-specific hybridization leading to mRNA degradation (e.g., via RNase H) or translational repression.